Analyst Price Targets — ORIC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 15, 2026 9:09 am | — | Goldman Sachs | $15.00 | $8.34 | TheFly | Oric Pharmaceuticals moved to Buy rating at Goldman Sachs |
| February 24, 2026 3:50 pm | Robert Burns | H.C. Wainwright | $25.00 | $13.27 | TheFly | Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright |
| February 24, 2026 5:34 am | Matthew Biegler | Oppenheimer | $15.00 | $11.71 | StreetInsider | Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC) |
| January 7, 2026 10:19 am | Kelsey Goodwin | Piper Sandler | $22.00 | $8.14 | TheFly | Oric Pharmaceuticals initiated with an Overweight at Piper Sandler |
| December 8, 2025 11:15 am | — | Wells Fargo | $25.00 | $11.00 | TheFly | Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo |
| November 14, 2025 3:58 pm | — | H.C. Wainwright | $23.00 | $12.78 | TheFly | Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright |
| September 4, 2025 9:21 am | Brad Canino | Guggenheim | $18.00 | $10.60 | TheFly | Oric Pharmaceuticals assumed with a Buy at Guggenheim |
| May 6, 2025 11:45 am | Matthew Biegler | Oppenheimer | $12.00 | $5.04 | TheFly | Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer |
| September 5, 2024 4:13 pm | Bradley Canino | Stifel Nicolaus | $20.00 | $9.48 | TheFly | Oric Pharmaceuticals initiated with a Buy at Stifel |
| March 21, 2024 6:32 am | Robert Burns | H.C. Wainwright | $21.00 | $14.59 | StreetInsider | ORIC Pharamceuticals (ORIC) PT Raised to $21 at H.C. Wainwright following 2023 results |
Latest News for ORIC
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address…
SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2026 (the “Grant Date”), ORIC granted a total of 44,400 non-qualified stock options and 7,200 restricted stock units to three new non-executive employees who…
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ORIC.
U.S. House Trading
No House trades found for ORIC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.